A Novel lncRNA TCLlnc1 Promotes Peripheral T Cell Lymphoma Progression through Acting as a Modular Scaffold of HNRNPD and YBX1 Complexes

In this research, a novel lncRNA was identified overexpressed in the main subtypes of peripheral T cell lymphoma, and designated as T cell lymphoma-associated lncRNA1.
[Cell Death & Disease]
Zhao, P., Ji, M.-M., Fang, Y., Li, X., Yi, H.-M., Yan, Z.-X., Cheng, S., Xu, P.-P., Janin, A., Wang, C.-F., Wang, L., & Zhao, W.-L. (2021). A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes. Cell Death & Disease, 12(4), 1–14. https://doi.org/10.1038/s41419-021-03594-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

FYN–TRAF3IP2 Induces NF-κB Signaling-Driven Peripheral T-Cell Lymphoma

Consistent with a driver oncogenic role, FYN–TRAF3IP2 expression in hematopoietic progenitors induced NF-κB-driven T-cell transformation in mice and cooperated with loss of the Tet2 tumor suppressor in peripheral T-cell lymphoma development.
[Nature Cancer]
FYN – TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma | Nature Cancer. (n.d.). Retrieved January 22, 2021, from https://www.nature.com/articles/s43018-020-00161-w Cite
Abstract
Bookmark

No account yet? Register

0
Share

Combination of Anti-PD-1 Antibody with P-GEMOX as a Potentially Effective Immunochemotherapy for Advanced Natural Killer/T Cell Lymphoma

Scientists report the efficacy of anti-programmed death 1 antibody with the P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) regimen in advanced natural killer/T cell lymphoma.
[Signal Transduction and Targeted Therapy]
Cai, J., Liu, P., Huang, H., Li, Y., Ma, S., Zhou, H., Tian, X., Zhang, Y., Gao, Y., Xia, Y., Zhang, X., Yang, H., Li, L., & Cai, Q. (2020). Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduction and Targeted Therapy, 5(1), 1–9. https://doi.org/10.1038/s41392-020-00331-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Allogeneic Stem Cell Transplantation in Poor Prognosis Peripheral T-cell Lymphoma: The Impact of Different Donor Type on Outcome

Scientists report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving transplantation from haploidentical or from conventional donors. The four-year OS, PFS, 2-year cumulative incidence of relapse and 2-year GRFS was 75%, 70%, 21%, and 51%, respectively.
[Bone Marrow Transplantation]
Castagna, L., Pagliardini, T., Bramanti, S., Schiano de Colella, J. M., Montes de Oca, C., Bouabdallah, R., Mariotti, J., Fürst, S., Granata, A., De Philippis, C., Harbi, S., Sarina, B., Legrand, F., Maisano, V., Weiller, P. J., Chabannon, C., Carlo-Stella, C., Santoro, A., Blaise, D., & Devillier, R. (2020). Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplantation, 1–7. https://doi.org/10.1038/s41409-020-01133-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Independent Evolution of Cutaneous Lymphoma Subclones in Different Microenvironments of the Skin

By sequencing the exomes of the microdissected clusters of lymphoma cells from the epidermis and the dermis, scientists found that those microenvironments comprised different malignant clonotypes.
[Scientific Reports]
Iyer, A., Hennessey, D., O’Keefe, S., Patterson, J., Wang, W., Wong, G. K.-S., & Gniadecki, R. (2020). Independent evolution of cutaneous lymphoma subclones in different microenvironments of the skin. Scientific Reports, 10(1), 15483. https://doi.org/10.1038/s41598-020-72459-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Astex Pharmaceuticals Announces that Tolinapant (ASTX660), a Novel Antagonist of Cellular and X-linked Inhibitors of Apoptosis Proteins, Has Been Granted Orphan Drug Designation for the Treatment of T-cell Lymphomas by the US FDA

Astex Pharmaceuticals, Inc. announced that the FDA has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins, tolinapant, for the treatment of T-cell lymphoma.
[Astex Pharmaceuticals, Inc]
Press Release
Bookmark

No account yet? Register

0
Share

LW-213 Induces Cell Apoptosis in Human Cutaneous T-cell Lymphomas by Activating PERK–eIF2α–ATF4–CHOP Axis

Researchers showed that LW-213 dose-dependently inhibited human cutaneous T-cell lymphoma cell lines with IC50 values of around 10 μM, meanwhile it potently inhibited primary leukemia cells derived from peripheral blood of T-cell lymphoma patients.
[Acta Pharmacologica Sinica]
Yu, X., Zhu, M., Wang, J., Li, H., Hu, P., Qing, Y., Wang, X., Wang, H., Wang, Z., Xu, J., Guo, Q., & Hui, H. (2020). LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK–eIF2α–ATF4–CHOP axis. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0466-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share